This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stallard, N. Articles by Indans, I. Search for Related Content PubMed PubMed Citation Articles by Stallard, N. Articles by Indans, I. Social Bookmarking                         What's this?

Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure

MPS Research Unit, The University of Reading, PO Box 240, Earley Gate, Reading RG6 6FN, UK n.stallard{at}reading.ac.uk

Anne Whitehead

Medical and Pharmaceutical Statistics Research Unit, The University of Reading, Reading, UK

Ian Indans

Bootle, Merseyside, UK

The conventional method for the assessment of acute dermal toxicity (OECD Test Guideline 402, 1987) uses death of animals as an endpoint to identify the median lethal dose (LD₅₀). A new OECD Testing Guideline called the dermal fixed dose procedure (dermal FDP) is being prepared to provide an alternative to Test Guideline 402. In contrast to Test Guideline 402, the dermal FDP does not provide a point estimate of the LD₅₀, but aims to identify that dose of the substance under investigation that causes clear signs of nonlethal toxicity. This is then used to assign classification according to the new Globally Harmonised System of Classification and Labelling scheme (GHS). The dermal FDP has been validated using statistical modelling rather than by in vivo testing. The statistical modelling approach enables calculation of the probability of each GHS classification and the expected numbers of deaths and animals used in the test for imaginary substances with a range of LD₅₀ values and dose-response curve slopes. This paper describes the dermal FDP and reports the results from the statistical evaluation. It is shown that the procedure will be completed with considerably less death and suffering than guideline 402, and will classify substances either in the same or a more stringent GHS class than that assigned on the basis of the LD₅₀ value.

Key Words: acute dermal toxicity testing • LD50 test • median lethal dose • OECD Test Guideline 402

Human & Experimental Toxicology, Vol. 23, No. 8, 405-412 (2004)
DOI: 10.1191/0960327104ht465oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Hoffmann, U. Luderitz-Puchel, T. Montag, and T. Hartung Optimisation of pyrogen testing in parenterals according to different pharmacopoeias by probabilistic modelling Innate Immunity, February 1, 2005; 11(1): 25 - 31. [Abstract] [PDF]